{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:14:38Z","timestamp":1773951278387,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tamoxifen is administered for estrogen receptor positive (ER<jats:sup>+<\/jats:sup>) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER<jats:sup>+<\/jats:sup> breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration. In this study, we found that anordrin, marketed as an antifertility medicine in China, inhibited tamoxifen-induced endometrial epithelial cell mitosis and NAFLD in mouse uterus and liver as an anti-estrogenic and estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, the active metabolite of anordrin, weakly bound to the ligand binding domain of ER-\u03b1. Anordrin did not regulate the classic estrogen nuclear pathway; thus, it did not affect the anti-tumor activity of tamoxifen in nude mice. Taken together, these data suggested that anordrin could eliminate the side effects of tamoxifen without affecting its anti-tumor activity.<\/jats:p>","DOI":"10.1038\/srep43940","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T10:41:59Z","timestamp":1488883319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity"],"prefix":"10.1038","volume":"7","author":[{"given":"Wenwen","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bubing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengshui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijie","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,7]]},"reference":[{"key":"BFsrep43940_CR1","first-page":"57","volume":"5","author":"GL Smith","year":"2014","unstructured":"Smith, G. L. The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. J Adv Pract Oncol. 5, 57\u201360 (2014).","journal-title":"J Adv Pract Oncol"},{"key":"BFsrep43940_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer. a randomised trial. Lancet. 381, 805\u201316 (2013).","journal-title":"Lancet"},{"key":"BFsrep43940_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 90, 1371\u20131388 (1998).","journal-title":"Journal of the National Cancer Institute"},{"key":"BFsrep43940_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1126\/science.1106943","volume":"307","author":"CM Revankar","year":"2005","unstructured":"Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B. & Prossnitz, E. R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 307, 1625\u201330 (2005)","journal-title":"Science"},{"key":"BFsrep43940_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bbrc.2005.08.226","volume":"336","author":"Z Wang","year":"2005","unstructured":"Wang, Z. et al. Identification, cloning, and expression of human estrogen receptor-\u03b136, a novel variant of human estrogen receptor-\u03b166. Biochem Biophys Res Commun. 336, 1023\u20131027 (2005).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep43940_CR6","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.2008.17.2254","volume":"27","author":"L Shi","year":"2009","unstructured":"Shi, L. et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol. 27, 3423\u20139 (2009).","journal-title":"J Clin Oncol"},{"key":"BFsrep43940_CR7","doi-asserted-by":"publisher","first-page":"e30174","DOI":"10.1371\/journal.pone.0030174","volume":"7","author":"X Zhang","year":"2012","unstructured":"Zhang, X., Ding, L., Kang, L. & Wang, Z. Y. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One. 7, e30174 (2012).","journal-title":"PLoS One."},{"key":"BFsrep43940_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/me.2009-0317","volume":"24","author":"L Kang","year":"2010","unstructured":"Kang, L. et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 24, 709\u201321 (2010).","journal-title":"Mol Endocrinol."},{"key":"BFsrep43940_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","volume":"418","author":"ZY Wang","year":"2015","unstructured":"Wang, Z. Y. & Yin, L. Estrogen receptor alpha-36 (ER-\u03b136): A new player in human breast cancer. Mol Cell Endocrinol. 418, 193\u2013206 (2015).","journal-title":"Mol Cell Endocrinol"},{"key":"BFsrep43940_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0039-128X(82)90113-1","volume":"40","author":"RR Mehta","year":"1982","unstructured":"Mehta, R. R., Jenco, J. M., Chatterton, R. T. Jr. & Venton, D. Antagonist of the actions of estrogens, androgens and progesterone by anordrin (2\u03b1,17\u03b1-diethynyl-A-nor-5\u03b1-androstane-2\u03b2,17\u03b2-diol dipropionate). Steroids. 40, 65\u201380 (1982).","journal-title":"Steroids"},{"key":"BFsrep43940_CR11","doi-asserted-by":"publisher","first-page":"26683","DOI":"10.1074\/jbc.M601522200","volume":"281","author":"JE O\u2019Brien","year":"2006","unstructured":"O\u2019Brien, J. E. et al. Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. J Biol Chem. 281, 26683\u201392 (2006).","journal-title":"J Biol Chem"},{"key":"BFsrep43940_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/0039-128X(81)90086-6","volume":"38","author":"RR Mehta","year":"1981","unstructured":"Mehta, R. R., Jenco, J. M. & Chatterton. R. T. Jr. Antiestrogenic and antifertility actions of Anordrin (2 alpha, 17 alpha-diethynyl-A-nor-5 alpha-androstane-2 beta, 17 beta-diol 2,17-dipropionate). Steroids. 38, 679\u201391 (1981).","journal-title":"Steroids"},{"key":"BFsrep43940_CR13","doi-asserted-by":"publisher","first-page":"e9013","DOI":"10.1371\/journal.pone.0009013","volume":"5","author":"SL Lin","year":"2010","unstructured":"Lin, S. L. et al. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK\/ERK and PI3K\/Akt pathways. PLoS One. 5, e9013 (2010).","journal-title":"PLoS One"},{"key":"BFsrep43940_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/en.2008-0623","volume":"150","author":"UE M\u00e5rtensson","year":"2009","unstructured":"M\u00e5rtensson, U. E. et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 150, 687\u201398 (2009).","journal-title":"Endocrinology"},{"key":"BFsrep43940_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.mce.2013.07.007","volume":"377","author":"C Weigt.","year":"2013","unstructured":"Weigt. C. et al. Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats. Mol Cell Endocrinol. 377, 147\u201358 (2013).","journal-title":"Mol Cell Endocrinol"},{"key":"BFsrep43940_CR16","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1093\/emboj\/19.17.4688","volume":"19","author":"G Flouriot","year":"2000","unstructured":"Flouriot, G. et al. identification of a new isoform of the human estrogen receptor-alpha (hER-a) that is encoded by distinct transcripts and that is able to repress hER-a activation function 1. EMBO J. 19, 4688\u2013700 (2000).","journal-title":"EMBO J"},{"key":"BFsrep43940_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.mce.2010.03.013","volume":"323","author":"CM Klinge","year":"2010","unstructured":"Klinge, C. M. et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol Cell Endocrinol. 323, 268\u201376 (2010).","journal-title":"Mol Cell Endocrinol"},{"key":"BFsrep43940_CR18","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1096\/fj.09-138305","volume":"24","author":"R Nehra","year":"2010","unstructured":"Nehra, R. et al. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 24, 2040\u201355 (2010).","journal-title":"FASEB J"},{"key":"BFsrep43940_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2407-14-172","volume":"14","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer 14, 172 (2014).","journal-title":"BMC Cancer"},{"key":"BFsrep43940_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1095\/biolreprod.108.071175","volume":"80","author":"C Otto","year":"2009","unstructured":"Otto, C. et al. GPR30 Does Not Mediate Estrogenic Responses in Reproductive Organs in Mice. Biology of Reproduction. 80, 34\u201341 (2009).","journal-title":"Biology of Reproduction"},{"key":"BFsrep43940_CR21","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1073\/pnas.0603339103","volume":"103","author":"Z Wang","year":"2006","unstructured":"Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y. & Deuel, T. F. A. variant of estrogen receptor-\u03b1, hER-\u03b136: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103(24), 9063\u20138 (2006).","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep43940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43940","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep43940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:37:26Z","timestamp":1671842246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep43940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,28]]}},"alternative-id":["BFsrep43940"],"URL":"https:\/\/doi.org\/10.1038\/srep43940","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,7]]},"assertion":[{"value":"26 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43940"}}